BONUS EPISODE: Pandemic Perspectives with John C. Martin

Over the next several weeks Distillations will be talking to people with special insight into the coronavirus crisis—biomedical researchers, physicians, public health experts, and historians.

In this episode we speak with John C. Martin, a biomedical researcher and former CEO of Gilead Sciences. Gilead is a pharmaceutical giant best known for its antiviral therapies for HIV/AIDS and hepatitis, but it’s also the company behind remdesivir, an antiviral drug that has recently made headlines as a possible treatment for COVID-19.

Martin talked to senior producer Mariel Carr about remdesivir, antiviral treatments for HIV and other illnesses, and working with Anthony “Tony” Fauci.

Credits

Hosts: Alexis Pedrick and Elisabeth Berry Drago Senior Producer: Mariel Carr Producer: Rigoberto Hernandez Music: "Balti," "Tuck and Point," and "Slimheart" by Blue Dot Sessions.

Research Notes

"Fauci: New Drug Remdesivir Cuts Down Coronavirus Recovery Time," NBC Nightly News. April 29, 2020.